
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI is supported by a powerful combination of accelerating diagnostics demand, expanding pricing leverage, and a fast-growing data franchise that together improved 3Q26 revenue to $411.5M, up 23.1% YoY, while adjusted EBITDA reached $25.6M and FY2026 revenue guidance was nudged to $1,600-1,605M. Oncology remains the core engine, with testing volume up 32% YoY to about 101,500 tests, xF order requisitions up 25% YoY, and higher ASPs expected from xT CDx migration and potential xF reimbursement gains later in 2027. The company’s moat is further reinforced by $550M+ of year-to-date data-licensing bookings, long-duration pharma contracts, and the Personalis acquisition, which should deepen MRD adoption and improve revenue visibility across multiple therapeutic areas.
Bears say
Tempus AI is viewed negatively because its diagnostics business faces execution and focus risks tied to a commercial partner, while demand from pharma customers can swing quarter to quarter as budgets and ordering priorities change. The company also depends on volatile ordering patterns and funding from the U.S. Department of Veterans Affairs for the Million Veteran Program, creating another layer of revenue uncertainty. Even if a deal-related upside exists, the core thesis remains fragile because closing risk could force PSNL to increase spending and investment, pressuring fundamentals rather than improving them.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Tempus AI Inc (TEM) Forecast
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares